NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (NRx ), a clinical-stage biopharmaceutical company, announced on Thursday that it has appointed an interim chief financial officer through an agreement with LS Associates, a division of LifeSci Advisors, LLC ('LSA').

LSA will offer certain consulting services to the company under the agreement, including arranging for the provision of the firm's interim chief financial officer. NRx has named Richard Narido as its interim chief financial officer.

Narido has held the position of chief financial officer of Lucira Health. He has served in various roles at Assembly Biosciences, Inc., including most recently as executive director, Finance, Controllership and Treasury. He has worked in various roles at Bio-Rad Laboratories, Inc., including as Americas Head of Finance, Global Commercial Operations, and in various finance and other roles, including Global Head Finance Reporting and Accounting for Novartis Vaccines and Diagnostics for McKesson Corporation. He started his career with PricewaterhouseCoopers's Financial Audit and Assurance practice.